Skip to Content
77 Mass Ave

Medicare myth

Spending is mostly not being wasted on futile end-of-life care.
August 22, 2018
Photo of a hospital hallway.
Photo of a hospital hallway.
Photo of a hospital hallway.Naoki Takano | Flickr

Around 25 percent of US Medicare spending occurs in the last year of life. Does that mean society is throwing large amounts of medical treatment at some patients in a futile, if noble, effort to extend lives that are bound to end soon?

A study coauthored by economics professor Amy Finkelstein offers a resounding answer: No.

After examining millions of medical records, the researchers found that although Medicare spending is concentrated among people who end up dying, little of it goes to patients whose death within the year was judged highly likely. For example, less than 5 percent is applied to patients in the single highest-risk percentile—and their predicted one-year mortality rate is still just 46 percent.

“Very little money is spent on people who we know with high probability are going to die in a short amount of time,” says Finkelstein.

The study used machine learning to evaluate the impact of a range of variables, producing a probability of death within one year for each patient. It revealed that fewer than 10 percent of people who die in a given year have a predicted one-year mortality rate over 50 percent. And even when people are admitted to a hospital in their last year of life, fewer than 4 percent have a predicted one-year mortality rate of 80 percent or higher at the time of admission.

The study shows that even relatively low-mortality health scenarios for the elderly will include some deaths—not that individual treatment decisions represent long-shot cases.

Keep Reading

Most Popular

Rendering of Waterfront Toronto project
Rendering of Waterfront Toronto project

Toronto wants to kill the smart city forever

The city wants to get right what Sidewalk Labs got so wrong.

Muhammad bin Salman funds anti-aging research
Muhammad bin Salman funds anti-aging research

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging

The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

Yann LeCun
Yann LeCun

Yann LeCun has a bold new vision for the future of AI

One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.

images created by Google Imagen
images created by Google Imagen

The dark secret behind those cute AI-generated animal images

Google Brain has revealed its own image-making AI, called Imagen. But don't expect to see anything that isn't wholesome.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.